All six director nominees elected, Deloitte ratified, say-on-pay approved at Ginkgo 2026 annual meeting

Ginkgo Bioworks Holdings, Inc.

Shareholders present: 39.5M Class A and 8.4M Class B shares, representing 77.15% of combined voting power.
All six directors elected: Jason Kelly and Reshma Shetty (Class B vote), Ross Fubini, Christian Henry, Sri Kosuri, Harry E. Sloan (single class).
Ratification of Deloitte & Touche as auditor for FY2026 approved: 119.5M for, 267k against, 3.8M abstentions.
Advisory vote to approve executive compensation passed: 95.1M for, 12.5M against, 4.2M abstentions (broker non-votes 11.8M).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ginkgo Bioworks Holdings, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers.

Proposal: say on pay
Outcome: passed

Exact text from the filing

Pursuant to the foregoing vote, the compensation of the Company’s named executive officers was approved on an advisory basis.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ginkgo Bioworks Holdings, Inc. shareholders approved Election of six nominees to serve as directors at the 2026-06-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-11

Exact text from the filing

Pursuant to the foregoing votes, the six nominees listed above were elected to serve on the Company’s Board of Directors.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Ginkgo Bioworks Holdings, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-12-31

Exact text from the filing

Pursuant to the foregoing vote, the ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved.

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-042932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.